Where is the coronavirus? The CDC says it isn’t available.

The CDC document is titled, “CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.” It is dated July 13, 2020.

Buried deep in the document, on page 39, in a section titled, “Performance Characteristics,” we have this: “Since no quantified virus isolates of the 2019-nCoV are currently available, assays [diagnostic tests] designed for detection of the 2019-nCoV RNA were tested with characterized stocks of in vitro transcribed full length RNA…”

The key phrase there is: “Since no quantified virus isolates of the 2019-nCoV are currently available…”

Every object that exists can be quantified, which is to say, measured. The use of the term “quantified” in that phrase means: the CDC has no measurable amount of the virus, because it is unavailable. THE CDC HAS NO VIRUS.

A further tip-off is the use of the word ‘isolates.” This means NO ISOLATED VIRUS IS AVAILABLE.

Another way to put it: NO ONE HAS AN ISOLATED SPECIMEN OF THE COVID-19 VIRUS.

NO ONE HAS ISOLATED THE COVID-19 VIRUS.

THEREFORE, NO ONE HAS PROVED THAT IT EXISTS.

[link to blog.nomorefakenews.com (secure)]

From page 39:

[link to www.fda.gov (secure)]

Performance Characteristics

Analytical Performance:

Limit of Detection (LoD):

LoD studies determine the lowest detectable concentration of (2019-nCoV) at which approximately 95% of all (true positive) replicates test positive. The LoD was determined by limiting dilution studies using characterized samples.

The analytical sensitivity of the rRT-PCR assays contained in the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel were determined in Limit of Detection studies. Since no quantified virus isolates of the 2019-nCoV are currently available, assays designed for detection of the 2019-nCoV RNA were tested with characterized stocks of in vitro transcribed full length RNA (N gene; GenBank accession: MN908947.2) of known titer (RNA copies/μL) spiked into a diluent consisting of a suspension of human A549 cells and viral transport medium (VTM) to mimic clinical specimen. Samples were extracted using the QIAGEN EZ1 Advanced XL instrument and EZ1 DSP Virus Kit (Cat# 62724) and manually with the QIAGEN DSP Viral RNA Mini Kit (Cat# 61904). Real-Time RT-PCR assays were performed using the ThemoFisher Scientific TaqPath™ 1-Step RT-qPCR Master Mix, CG (Cat# A15299) on the Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument according to the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel instructions for use.


A preliminary LoD for each assay was determined testing triplicate samples of RNA purified using each
extraction method. The approximate LoD was identified by extracting and testing 10-fold serial dilutions of characterized stocks of in vitro transcribed full-length RNA. A confirmation of the LoD was determined using 3-fold serial dilution RNA samples with 20 extracted replicates. The LoD was determined as the lowest concentration where ≥ 95% (19/20) of the replicates were positive.

Last Edited by Happy in Nature on 10/08/2020 03:40 PM